NCT05108545 is a Phase 3 clinical trial of Amphotericin B liposomes in Neutropenia and Fever, sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd..

Who is sponsoring NCT05108545?

NCT05108545 is sponsored by CSPC ZhongQi Pharmaceutical Technology Co., Ltd..

What drugs are being tested in NCT05108545?

Interventions in NCT05108545: Amphotericin B liposomes.

What condition does NCT05108545 study?

NCT05108545 studies Neutropenia and Fever.

Is NCT05108545 still recruiting?

NCT05108545 is currently status unknown. Last updated 5 November 2021.

Last reviewed 2021-11-05 · How we verify

NCT05108545

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of Amphotericin B Liposome for Injection in Patients With Persistent Neutropenia and Fever

Status unknown Phase 3 Last updated 5 November 2021

What this trial tests

Phase 3 trial testing Amphotericin B liposomes in Neutropenia and Fever in 93 participants. Status unknown.

Timeline

15 December 2021

Primary endpoint
31 July 2022

15 January 2023

Quick facts

Lead sponsor	CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase	Phase 3
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	93
Start date	15 December 2021
Primary completion	31 July 2022
Estimated completion	15 January 2023

Drugs / interventions tested

Amphotericin B liposomes — full drug profile →

Conditions studied

Neutropenia and Fever — all drugs for Neutropenia and Fever →

Sponsor

CSPC ZhongQi Pharmaceutical Technology Co., Ltd. — full company profile →

Who can join

Adults 18 to 75, any sex, with Neutropenia and Fever. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multicenter, open-label, single-arm, phase III study to evaluate the safety and efficacy of Amphotericin B liposomes in patients with persistent neutropenia and fever.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Inorganic Nanoparticles: Tools to Emphasize the Janus Face of Amphotericin B.
Boudier A, Mammari N, Lamouroux E, Duval RE. · · 2023 · cited 1× · PMID 37887244 · DOI 10.3390/antibiotics12101543

Verify or expand the search:

Other CSPC ZhongQi Pharmaceutical Technology Co., Ltd. trials

Trials by the same sponsor.

NCT07532655 — A Single Ascending Dose Study of SYH2082 Injection in Healthy Participants · Phase 1 · not yet recruiting
NCT07412353 — A Single Ascending Dose Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SYH2085 · Phase 1 · recruiting
NCT07282509 — Safety and Efficacy of Paclitaxel Liposome Arterial Infusion Combined With Systemic Therapy for Second-Line Treatment of · Phase 1, PHASE2 · not yet recruiting
NCT07418736 — A Phase II Study of CM326 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2 · recruiting
NCT07241936 — A Study of Sirolimus (Albumin-Bound) in Combination With Different ADCs Treatment of Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05108545 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Last refreshed: 5 November 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05108545.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing